Catestatin as a Target for Treatment of Inflammatory Diseases

Muntjewerff, Elke M.; Dunkel, Gina; Nicolasen, Mara J.T.; Mahata, Sushil K.; Bogaart, Geert van den

doi:10.3389/fimmu.2018.02199

Cited by 55 publications

(62 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBD diagnosis was made in accordance with the latest guidelines of the European Crohn's and Colitis Organization and the European Society of Gastrointestinal and Abdominal Radiology [34]. The following inclusion criteria were used: disease duration of at least one year and stable disease activity in the previous 3 months.…”

Section: Subjectsmentioning

confidence: 99%

“…Disease severity in patients with Crohn's disease was assessed using simple endoscopic score (SES-CD), the Crohn's disease activity index (CDAI) and the Harvey Bradshaw index (HBI) [37][38][39]. According to the latest ECCO guidelines, clinical indices should be carefully used since they are not well-validated in the clinical practice and discrepancies could be seen [34]. Therefore, we have stratified our patients using only endoscopic index score, while clinical index scores were only descriptively reported.…”

Section: Assessment Of Disease Severitymentioning

confidence: 99%

See 1 more Smart Citation

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Živković

Matetić

Hadjina

et al. 2020

JCM

View full text Add to dashboard Cite

Catestatin (CST) is an important peptide in the pathophysiology of chronic inflammatory disorders. However, clinical studies on inflammatory bowel disease (IBD) patients are lacking. Our goal was to investigate CST concentrations in IBD patients compared to healthy subjects. Additionally, we aimed to determine arterial stiffness parameters in relation to CST. This cross-sectional study compared 80 IBD patients (45 Crohn’s disease (CD) and 35 ulcerative colitis (UC) patients) with 75 control subjects. Serum CST levels were significantly higher in the IBD group compared to control subjects (11.29 ± 9.14 vs. 7.13 ± 6.08 ng/mL, p = 0.001) and in the UC group compared to CD patients (13.50 ± 9.58 vs. 9.03 ± 6.92 ng/mL, p = 0.021), irrespective of age and BMI. IBD patients exhibited significantly higher values of heart rate adjusted central augmentation index (cAIx-75) (14.88 ± 10.59 vs. 6.87 ± 9.50 %, p < 0.001) and pulse wave velocity (PWV) (8.06 ± 3.23 vs. 6.42 ± 1.47 m/s, p < 0.001) compared to control group. Furthermore, PWV was the only significant independent correlate of CST (B = 1.20, t = 4.15, p < 0.001), while CST, PWV, cAIx-75, high-sensitivity C-reactive protein and BMI were significant predictors of positive IBD status (1.089 (1.022–1.161), 1.515 (1.166–1.968), 1.060 (1.024–1.097), 1.458 (1.116–1.906), 0.793 (0.683–0.920), respectively). Serum CST levels were significantly higher in IBD patients compared to controls and an independent positive correlation of CST with PWV existed. Therefore, it is possible that CST could have a role in the complex pathophysiology of IBD and its cardiovascular complications.

show abstract

Section: Subjectsmentioning

confidence: 99%

Section: Assessment Of Disease Severitymentioning

confidence: 99%

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Živković

Matetić

Hadjina

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Peptide Cst is a 21 amino acid-residue, which derives from chromogranin-A cleavage [31][32][33]. CST involved in the regulation of many natural and pathological physiological processes, for example, in in ammation [37][38][39]. Importantly, CST is reported to play crucial roles in the neuronal system [36], and contained an anti-hypertensive effect in the cardiovascular system.…”

Section: Discussionmentioning

confidence: 99%

“…CST is wellestablished to act as a potent inhibitor of nicotine-evoked catecholamine secretion in vitro and in vivo and represents a novel, autocrine homeostatic mechanism controlling catecholamine release from chroma n cells and noradrenergic neurons [35]. In mammals, Cst is observed mainly expressed and secreted in granule cells and adrenergic neurons [36], and reported to be involved in the regulation of many natural and pathological physiological processes [37][38][39]. Moreover, CST is reported to play crucial roles in the neuronal system [36], and contained an anti-hypertensive effect in the cardiovascular system.…”

Section: Introductionmentioning

confidence: 99%

Catestatin (Cst) protects the brain against ischemia/reperfusion injury through suppressing ER-stress and mitochondrial dysfunction

Bing¹,

Song²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCerebral stroke, known as a cerebral vascular accident (CVA), is one of the leading causes of long-term disability and the second leading cause of death worldwide. Despite amounts of advances that have been achieved in terms of the treatment of ischemic stroke. But thus far, clinically effective neuroprotectants remain elusive, which may mainly due to the lack of a complete understanding of molecular mechanisms of the stroke. Previous studies have been revealed that catestatin (Cst) is closely related to cardiovascular ischemia/reperfusion injuries. However, little is known about whether Cst is involved in the regulation of neuronal death processes during ischemia. MethodsIn the present study, we revealed a protective function of Cst on Rat neuron cell death in the setting of ischemia/reperfusion injury. ResultsWe found that Cst treatment significantly attenuated the deficits of hippocampal related behaviors. On mechanism, our data revealed that Cst administration remarkably reduced ER-stress and mitochondrial dysfunction caused by I/R injury, and subsequently protected brain cells from apoptosis. ConclusionIn sum, our results demonstrate that Cst ameliorates I/R injury-induced hippocampal-related behaviors deficits by protecting the neurons from I/R injury-induced ER-stress and mitochondrial dysfunction and apoptosis. Our findings may provide a promising novel neuroprotectant for ischemic stroke therapy.

show abstract

“…Chromogranin A (CgA), a 439 amino acid prohormone and granulogenic factor that has pleiotropic roles in regulating various organ systems, was recently identified as a potentially important regulatory factor in obesity . Proteolytic cleavage of CgA by enzymes such as prohormone convertases, cathepsin L, plasmin, and kallikrein results in the production of a variety of active peptides, including catestatin (CgA 352‐372 ), which has the widest spectrum of biological activities . One of the main mechanisms of action of catestatin is the inhibition of catecholamine release through a non‐competitive blockage of nicotine receptors, which was first described in 1997 and subsequently supported by additional in vitro and in vivo studies .…”

Section: Introductionmentioning

confidence: 99%

Serum catestatin concentrations are decreased in obese children and adolescents

et al. 2019

View full text Add to dashboard Cite

Background: Catestatin is a chromogranin A-derived peptide with a wide spectrum of biological activities, such as inhibiting catecholamine release, decreasing blood pressure, stimulating histamine release, reducing beta-adrenergic stimulation, and regulating oxidative stress.Objectives: The aims of our study were to determine serum catestatin concentrations in obese children and adolescents in regard to presence or absence of metabolic syndrome (MS) and to evaluate the possible relations between catestatin levels and other cardiovascular risk factors.Subjects: Ninety-two obese subjects with a body mass index z score > 2, aged 10 to 18 years, and 39 healthy, normal weight controls were enrolled in the study.Methods: Serum catestatin concentrations were measured using an enzyme-linked immunosorbent assay.Results: Significantly lower serum catestatin concentrations were recorded in the group of obese subjects compared with a control group (10.03 ± 5.05 vs 13.13 ± 6.25 ng/mL, P = 0.004). Further analyses revealed significantly lower catestatin concentrations in the subgroup of obese patients with MS (9.02 ± 4.3 vs 10.54 ± 5.36 vs 13.13 ± 6.25, P = 0.008).Serum catestatin concentrations were significantly negatively correlated with diastolic blood pressure (r = −0.253, P = 0.014), homeostatic model assessment of insulin resistance (r = −0.215, P = 0.037) and high sensitivity C-reactive protein (r = −0.208, P = 0.044). Conclusions:To the best of our knowledge, this study is the first to report catestatin concentrations in obese children and adolescents and their possible relations with MS and cardiovascular risk factors in a pediatric population. Obese subjects with MS have lower serum catestatin concentrations than obese subjects without MS and controls. K E Y W O R D Sadolescents, catestatin, children, metabolic syndrome, obesity

show abstract

Catestatin as a Target for Treatment of Inflammatory Diseases

Cited by 55 publications

References 124 publications

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Serum Catestatin Levels and Arterial Stiffness Parameters Are Increased in Patients with Inflammatory Bowel Disease

Catestatin (Cst) protects the brain against ischemia/reperfusion injury through suppressing ER-stress and mitochondrial dysfunction

Serum catestatin concentrations are decreased in obese children and adolescents

Contact Info

Product

Resources

About